Sustained Release Ocular Drug Delivery Systems Report 2015 – 2025 with 2014 as the Base Year (PR Newswire)

DUBLIN, Aug. 05, 2015 /PRNewswire/ —

Research and Markets ( has announced the addition of the “Sustained Release Ocular Drug Delivery Systems, 2015 – 2025 (2nd edition)” report to their offering.

The Sustained Release Ocular Drug Delivery Systems, 2015 – 2025 (2nd edition)’ report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases.

The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry.

The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 – 2020 and 2020 – 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified.


– More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug.
– Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien.
– Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market.
– DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma.
– Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts.
– The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Product Profiles and Sales Forecast

6. Company Profiles

7. Venture Capital Support

8. Recent Partnerships

9. SWOT Analysis

10. Interview Transcripts

11. Conclusion

12. Appendix 1: Tabulated Data

13. Appendix 2: List Of Companies

Companies Mentioned

– 3i Plc
– AbbVie
– Abell Foundation
– Aciont, Inc.
– Actavis Plc
– Aerie Pharmaceutical
– Ain Shams University, Cairo, Egypt
– Alcon
– Alimera Sciences
– Allergan
– Alliance Medical Products Inc
– Alpha Associates
– Amgen Inc.
– Amorphex Therapeutics
– Apax Partners
– Ascension Health Ventures
– Atlas Venture
– Auritec Pharmaceuticals
– Avida Group
– Bausch & Lomb
– Baxter Venture
– Bayer Healthcare
– BCN Peptides
– Ben Venue Laboratories
– BioLight Israeli Life Sciences Investments Ltd.
– Brandon Biosciences
– Brecon Pharmaceuticals Ltd
– Brown Advisory
– Burrill and Company
– Byron Chemical Company
Caja Navarra
– Canaan Partners
– Can-Fite BioPharma
– Catania University, Catania, Italy
– Centre for Eye Research Australia (CERA)
– Chang Gung University
– Chiron Vision Corporation
– Chongqing Medical University
Clave Mayor
– Control Delivery Systems Inc.
– CorporaciĆ³n CAN
– Cullen Eye Institute, Baylor College of Medicine
– Domain Associates
– Duke Reading Center
Duke University Medical Center
– Economic Committee for Health Products
– Enigma Therapeutics
– Envisia Therapeutics
– Ergo Equity
– ESBATech (a Biomedical Research Unit of Alcon)
– Euclid Systems
– EVS Glaucoma Therapeutics
– Federal University of Minas Gerais
– Flextronics International Ltd
– ForSight Labs
– Genentech
– GP Pharm
– GrayBug
– Hatteras Venture Partners
– Health Ventures
– Hercules Technology Growth Capital
– Hospital Research Center, Linkoping University
– Icon Bioscience
– IIT Roorkee
– Innocore
– Institute for Advanced Chemistry of Catalonia
– Institute of Nanoscience and Nanotechnology, Barcelona
– Intersouth Partners
– InterWest Partners
– Intrinsiq
– Inveready
Johns Hopkins University School of Medicine
Kyoto University, Faculty of Medicine
– le Venture Partners
– Lowy Medical Research Institute (LMRI)
– Maryland Biotechnology Center
Maryland Venture
– Mati Therapeutics
– Mayflower
– Medicines and Healthcare products Regulatory Agency
Melbourne University
– Memorial Sloan Kettering Cancer Center
– Merlin Biosciences
MIT, Boston
– Monash University
– Morningside Group
– Nanomi
Nanyang Technological University, Singapore
– National Eye Institute
– National Institute for Health and Care Excellence (NICE)
– National Institutes of Health Clinical Center
– National Tsing Hua University
– Navarra Civic Banking
– Neurotech Pharma
– New Enterprise Associates
– Nexus Medical Partners
– Nishi Eye Hospital, Osaka, Japan
– Novagali Pharma
– Novartis
– Nuclear Magnetic Resonance Unit, Barcelona
– Oakwood Laboratories
– OctoPlus
– Ocular Therapeutix
– Oculex Pharmaceuticals
– OHR Pharmaceuticals
– On Demand Therapeutics
– OncoSil Medical
– Ora Inc.
– Pappas Ventures
– Pfizer
– Polaris Ventures
– Polyactiva
– Pound Capital
– ProRetina Therapeutics
– pSivida Corp
– QLT Inc.
– Rainbow Biosciences
– Real Fleece FCR
– Regeneron
– Replenish, Inc.
– Roche
– Sanofi
– Santen
– Sanwa Kagaku Kenkyusho
– Sao Paulo State University
– School of Pharmacy, West Virginia University
– Signet Healthcare Partners
– Singapore Eye Research Institute
– SKS Ocular LLC
– Sodena (Navarra Development Society )
– Sparta LLC
– Specialized Therapeutics
– SV Life Sciences
– Taiwan Liposome Company
– The EMMES Corporation
– TheraKine
Tulane University Medical Center
– United Centers for Advanced Research and Translational Medicine (ART)
University of Barcelona
University of California
University of Cincinnati
University of Colorado
University of Florida
University of Miami
University of Nebraska
University of Ottawa, Ottawa
University of Pittsburgh
– University of Porto
University of Waterloo
– Valeant Pharmaceuticals
– Venrock
– Versant Ventures
– Wakefield Group
Wayne State University
– West LB
– Wilmer Eye Institute at Johns Hopkins University
– World Health Organization
– Yuwa capital

For more information visit

Media Contact: Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets